S&P 500   3,116.39 (-0.38%)
DOW   26,957.59 (-0.46%)
QQQ   216.48 (+0.52%)
AAPL   292.65 (+1.59%)
FB   197.20 (+0.22%)
MSFT   170.17 (+1.25%)
GOOGL   1,390.47 (+0.30%)
AMZN   1,979.59 (+0.35%)
CGC   19.82 (+1.02%)
NVDA   267.65 (+2.14%)
BABA   208.74 (+1.52%)
MU   52.37 (+0.52%)
GE   10.95 (-3.27%)
TSLA   778.80 (-2.64%)
AMD   47.49 (-0.17%)
T   37.10 (-0.67%)
ACB   1.51 (+0.00%)
F   7.21 (-0.28%)
NFLX   379.24 (+5.32%)
PRI   120.14 (-1.05%)
BAC   30.63 (-1.45%)
DIS   123.36 (-3.77%)
GILD   74.70 (+6.56%)
S&P 500   3,116.39 (-0.38%)
DOW   26,957.59 (-0.46%)
QQQ   216.48 (+0.52%)
AAPL   292.65 (+1.59%)
FB   197.20 (+0.22%)
MSFT   170.17 (+1.25%)
GOOGL   1,390.47 (+0.30%)
AMZN   1,979.59 (+0.35%)
CGC   19.82 (+1.02%)
NVDA   267.65 (+2.14%)
BABA   208.74 (+1.52%)
MU   52.37 (+0.52%)
GE   10.95 (-3.27%)
TSLA   778.80 (-2.64%)
AMD   47.49 (-0.17%)
T   37.10 (-0.67%)
ACB   1.51 (+0.00%)
F   7.21 (-0.28%)
NFLX   379.24 (+5.32%)
PRI   120.14 (-1.05%)
BAC   30.63 (-1.45%)
DIS   123.36 (-3.77%)
GILD   74.70 (+6.56%)
S&P 500   3,116.39 (-0.38%)
DOW   26,957.59 (-0.46%)
QQQ   216.48 (+0.52%)
AAPL   292.65 (+1.59%)
FB   197.20 (+0.22%)
MSFT   170.17 (+1.25%)
GOOGL   1,390.47 (+0.30%)
AMZN   1,979.59 (+0.35%)
CGC   19.82 (+1.02%)
NVDA   267.65 (+2.14%)
BABA   208.74 (+1.52%)
MU   52.37 (+0.52%)
GE   10.95 (-3.27%)
TSLA   778.80 (-2.64%)
AMD   47.49 (-0.17%)
T   37.10 (-0.67%)
ACB   1.51 (+0.00%)
F   7.21 (-0.28%)
NFLX   379.24 (+5.32%)
PRI   120.14 (-1.05%)
BAC   30.63 (-1.45%)
DIS   123.36 (-3.77%)
GILD   74.70 (+6.56%)
S&P 500   3,116.39 (-0.38%)
DOW   26,957.59 (-0.46%)
QQQ   216.48 (+0.52%)
AAPL   292.65 (+1.59%)
FB   197.20 (+0.22%)
MSFT   170.17 (+1.25%)
GOOGL   1,390.47 (+0.30%)
AMZN   1,979.59 (+0.35%)
CGC   19.82 (+1.02%)
NVDA   267.65 (+2.14%)
BABA   208.74 (+1.52%)
MU   52.37 (+0.52%)
GE   10.95 (-3.27%)
TSLA   778.80 (-2.64%)
AMD   47.49 (-0.17%)
T   37.10 (-0.67%)
ACB   1.51 (+0.00%)
F   7.21 (-0.28%)
NFLX   379.24 (+5.32%)
PRI   120.14 (-1.05%)
BAC   30.63 (-1.45%)
DIS   123.36 (-3.77%)
GILD   74.70 (+6.56%)
Log in

OTCMKTS:RSLS - Reshape Lifesciences Stock Price, Forecast & News

$6.92
-0.18 (-2.54 %)
(As of 02/26/2020 04:00 PM ET)
Today's Range
$6.92
Now: $6.92
$6.92
50-Day Range
$5.22
MA: $7.55
$11.00
52-Week Range
$2.91
Now: $6.92
$46.68
Volume187 shs
Average Volume890 shs
Market Capitalization$2.42 million
P/E RatioN/A
Dividend YieldN/A
Beta2.06
ReShape Lifesciences Inc, a medical device company, focuses on the design and development of devices that use neuroblocking technology to treat obesity, metabolic diseases, and other gastrointestinal disorders. Its proprietary neuroblocking technology, vBloc Therapy is designed to intermittently block the vagus nerve using electrical impulses. The company's product portfolio includes ReShape vBloc, a therapy that enables patients to feel full and eat less by intermittently blocking hunger signals on the vagus nerve; and ReShape Balloon system that uses balloon technology designed to take up room in the stomach to enable people lose weight. Read More…

Industry, Sector and Symbol

Industry Electromedical equipment
Sub-IndustryHealth Care Equipment
SectorMedical
Current SymbolOTCMKTS:RSLS
CUSIP29365M20
Phone949-429-6680

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$610,000.00
Cash Flow$69.20 per share
Book Value$341.84 per share

Profitability

Net Income$-81,150,000.00
Net Margins-668.58%

Miscellaneous

EmployeesN/A
Market Cap$2.42 million
Next Earnings Date5/21/2020 (Estimated)
OptionableNot Optionable

Receive RSLS News and Ratings via Email

Sign-up to receive the latest news and ratings for RSLS and its competitors with MarketBeat's FREE daily newsletter.


Reshape Lifesciences (OTCMKTS:RSLS) Frequently Asked Questions

What is Reshape Lifesciences' stock symbol?

Reshape Lifesciences trades on the OTCMKTS under the ticker symbol "RSLS."

When did Reshape Lifesciences' stock split? How did Reshape Lifesciences' stock split work?

Shares of Reshape Lifesciences reverse split on Thursday, November 8th 2018. The 1-140 reverse split was announced on Wednesday, November 7th 2018. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, November 7th 2018. An investor that had 100 shares of Reshape Lifesciences stock prior to the reverse split would have 1 shares after the split.

How were Reshape Lifesciences' earnings last quarter?

Reshape Lifesciences Inc (OTCMKTS:RSLS) announced its quarterly earnings data on Tuesday, August, 14th. The medical device company reported ($672.00) EPS for the quarter, missing the consensus estimate of ($250.60) by $421.40. The medical device company earned $0.65 million during the quarter. Reshape Lifesciences had a negative return on equity of 163.22% and a negative net margin of 668.58%. View Reshape Lifesciences' Earnings History.

When is Reshape Lifesciences' next earnings date?

Reshape Lifesciences is scheduled to release their next quarterly earnings announcement on Thursday, May 21st 2020. View Earnings Estimates for Reshape Lifesciences.

Has Reshape Lifesciences been receiving favorable news coverage?

News coverage about RSLS stock has been trending extremely negative on Wednesday, InfoTrie Sentiment Analysis reports. The research firm identifies negative and positive media coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Reshape Lifesciences earned a daily sentiment score of -5.0 on InfoTrie's scale. They also assigned media coverage about the medical device company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the company's share price in the near future. View News Stories for Reshape Lifesciences.

Who are some of Reshape Lifesciences' key competitors?

What other stocks do shareholders of Reshape Lifesciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Reshape Lifesciences investors own include XOMA (XOMA), Synergy Pharmaceuticals (SGYP), CTI BioPharma (CTIC), DryShips (DRYS), La Jolla Pharmaceutical (LJPC), Neovasc (NVCN), Gilead Sciences (GILD), Progenics Pharmaceuticals (PGNX), CytRx (CYTR) and Clovis Oncology (CLVS).

Who are Reshape Lifesciences' key executives?

Reshape Lifesciences' management team includes the folowing people:
  • Mr. Dan W. Gladney, Chairman, Pres & CEO (Age 65)
  • Mr. Scott P. Youngstrom, CFO, Sr. VP of Fin. & Sec. (Age 58)
  • Mr. Naqeeb A. Ansari, VP of Worldwide Sales (Age 57)
  • Dr. Mark B. Knudson Ph.D., Co-Founder and Special Advisor to the CEO (Age 69)
  • Dr. Katherine S. Tweden Ph.D., Co-Founder (Age 57)

How do I buy shares of Reshape Lifesciences?

Shares of RSLS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Reshape Lifesciences' stock price today?

One share of RSLS stock can currently be purchased for approximately $6.92.

How big of a company is Reshape Lifesciences?

Reshape Lifesciences has a market capitalization of $2.42 million and generates $610,000.00 in revenue each year. View Additional Information About Reshape Lifesciences.

What is Reshape Lifesciences' official website?

The official website for Reshape Lifesciences is http://www.reshapelifesciences.com/.

How can I contact Reshape Lifesciences?

Reshape Lifesciences' mailing address is 1001 Calle Amanecer, Clemente CA, 92673. The medical device company can be reached via phone at 949-429-6680 or via email at [email protected]


MarketBeat Community Rating for Reshape Lifesciences (OTCMKTS RSLS)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  389 (Vote Outperform)
Underperform Votes:  395 (Vote Underperform)
Total Votes:  784
MarketBeat's community ratings are surveys of what our community members think about Reshape Lifesciences and other stocks. Vote "Outperform" if you believe RSLS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RSLS will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/26/2020 by MarketBeat.com Staff

Featured Article: Monthly Dividend Stocks

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel